GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...

McNamara has been with GSK since 2015, when he joined the company as head of consumer health for Europe and the Americas, and previously worked for 10 years at Novartis, ultimately heading up its ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK Consumer’s (GSK’s) Q2FY19 revenue, Ebitda and PAT growth of 14%, 35% and 43% y-o-y, respectively, surpassed estimates. This was the fourth consecutive quarter of strong volume spurt ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

View all information regarding the medicines that are manufactured by Glaxosmithkline Consumer Healthcare including its generic drug name, trade name, how to use, the price, and its composition.

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for ...